SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody | abx376490

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody is a recombinant Human Monoclonal Antibody expressed in CHO cells against SARS-CoV-2/COVID-19 Spike Protein RBD (Omicron B.1.1.529 Variant).
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The B.1.1.529 (Omicron) variant was identified in South Africa in November 2021. It possess a large number of mutations which appear to increase the risk of reinfection compared to other variants of concern.

Target: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Omicron B.1.1.529 Variant)
Clonality: Monoclonal
Reactivity: Virus
Expression: Recombinant
Tested Applications: ELISA, WB
Host: Human
Recommended dilutions: ELISA: 1/5000 - 1/10000, WB: 1/1000 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.
Conjugation: Unconjugated
Immunogen: SARS-CoV-2
Isotype: IgG1 Kappa
Form: Liquid
Purification: Purified by affinity chromatography.
Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.